OncologyTier 2Topic

Chest X-ray in oncology

Role

CXR remains a frequent first investigation in oncology - both for initial detection of a lung mass/lymphadenopathy and for monitoring known thoracic disease, though CT has largely superseded it for definitive staging
Often the first imaging test to raise suspicion of lung cancer, incidentally or in a symptomatic patient (cough, haemoptysis, weight loss)

Findings

A visible pulmonary nodule/mass, hilar/mediastinal lymphadenopathy, or pleural effusion on CXR can be the first sign of an underlying malignancy, though CXR has limited sensitivity for small lesions and cannot reliably characterise or stage a finding

Acting on findings

Any suspicious CXR finding (new mass, unexplained effusion, unresolving consolidation) warrants CT chest for characterisation - CXR alone is never sufficient to confirm or exclude malignancy
Repeat CXR at ~6 weeks post-pneumonia in smokers/older adults specifically to exclude an underlying obstructing malignancy masquerading as (or complicated by) infection

Monitoring

CXR is used for rapid, low-radiation monitoring of known thoracic disease (e.g. tracking a known effusion or checking line/tube position after a procedure) but is not used for formal oncological staging or response assessment, which require CT/PET

Associations

Lung cancer, malignant pleural effusion, mediastinal lymphadenopathy, post-obstructive pneumonia

Limitations

A normal CXR does not exclude malignancy - small nodules, early disease, and some mediastinal/hilar disease can be missed, and a high index of clinical suspicion should still prompt CT

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.

Get premium access